In-Silico Evaluation of FDA-Approved Drugs as PDE5 Inhibitors for Treatment of Hepatocellular Cancer
Abstract
Hepatocellular carcinoma (HCC) is a predominant cause of cancer-associated mortality, characterized by restricted treatment alternatives and unfavorable prognosis. Phosphodiesterase type 5 (PDE5) plays an important role in cancer development; thus, repurposing FDA-approved PDE5 inhibitors for HCC therapy, focusing on essential pathways like apoptosis and angiogenesis, would provide safe and effective treatment alternatives. This work seeks to assess the potential of FDA-approved drugs from the DrugBank library as PDE5 inhibitors against HCC-related targets by in-silico methods, thus identifying a safe and effective PDE5 inhibitor for HCC therapy. Molecular docking was conducted to evaluate the binding affinities of PDE5 inhibitors. Furthermore, ADMET profiling was performed utilizing web servers such as SwissADME, pkCSM, and ProTox to identify candidates possessing ideal drug-like characteristics. Molecular dynamics simulation was then utilized to confirm the stability and interactions of the highest-performing compounds. The best docked stable drug candidate was then docked with critical oncogenic proteins (PDE5, VEGFR-2, caspase-9, and caspase-7). Metabolite 4-hydroxy Nebivolol (DBMET02738) and Nabumetone ( ) had high docking scores of -12.781 and -12.573 kcal/mol with PDE5 and VEGFR-2 or Caspase-9, with excellent ADMET profiles and stability in the molecular dynamics simulation. Their binding affinities surpassed well-established drugs for HCC, such as Sorafenib or…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.